Colorectal Cancer Clinical Trial
Official title:
Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy
Primary Objectives:
- To determine the feasibility of a study that would describe changes of certain
circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis
factor-alpha [TNF] and symptoms related to chemoradiation therapy (pre-therapy, during
therapy and up to 3 months post-therapy) among patients with lung, esophageal, gastric,
colorectal and anal cancer.
- To determine the feasibility of studying neurocognitive function in patients with
non-small cell lung cancer (NSCLC) at presentation and during chemoradiation therapy to
determine the prevalence, severity, and pattern of cognitive symptoms.
One of the ways to learn about the symptoms of chemoradiation therapy is by looking at how
certain proteins called cytokines (found in the blood) change during therapy. Another way is
to look at how thinking and memory may be changed because of treatment.
Before therapy starts, you will be asked to complete several questionnaires during a visit
to the Radiation Oncology clinic at M. D. Anderson. These questionnaires measure physical
and emotional symptoms. These questionnaires should take about 30 minutes to finish. Lung
cancer patients will also complete some cognitive (mental) questionnaires. During this
visit, the research nurse will teach you how to use the telephone system for measuring
symptoms. You will tell the system the most convenient times for the telephone calls. The
date of the call will be at the same or close to the date of your weekly clinic visit.
Before you begin your chemoradiation treatments, you will have a sample of blood drawn
(around 2½ tablespoons). The sample of blood will be used to measure levels of cytokines in
your blood pre treatment.
You will have about 2½ tablespoons of blood drawn again when you start chemoradiation, and
then once a week while you are receiving treatment. These cytokines may be related to
symptoms experienced while having treatment for cancer. These blood tests are being done to
study the levels of cytokines in your blood during, and after treatment for cancer.
Symptoms will be monitored weekly using an interactive voice response telephone system.
During chemoradiation, the automated telephone system will call you once a week to ask you
to rate your symptoms and how much the symptoms interfere in your daily life. The
information collected by these calls is only being used for this research study.
At the end of the chemoradiation, lung cancer patients will again be given questionnaires to
measure cognitive symptoms.
For lung cancer patients who are post-chemotherapy, your symptoms will be monitored weekly
for 3 months after therapy using the interactive voice response telephone system. For
esophageal, gastric, colorectal, and anal patients who are post-therapy, your symptoms will
be monitored weekly for 6 weeks after therapy using the interactive voice response telephone
system. About 30 days after chemoradiation, you will have 2½ tablespoons of blood drawn at
your regularly scheduled clinic visit. If you are not scheduled for a 3 month clinic visit,
we will contact your local physician for blood lab results.
This is an investigational study. About 225 evaluable patients will take part in this study.
All will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |